Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 6 | 2025 | 295 | 2.270 |
Why?
|
| Karyopherins | 1 | 2025 | 6 | 0.960 |
Why?
|
| Autophagy | 2 | 2024 | 199 | 0.940 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2025 | 65 | 0.930 |
Why?
|
| Wnt Signaling Pathway | 1 | 2025 | 95 | 0.900 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2024 | 36 | 0.890 |
Why?
|
| Colonic Neoplasms | 2 | 2022 | 163 | 0.830 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2022 | 53 | 0.790 |
Why?
|
| NF-kappa B | 1 | 2024 | 329 | 0.780 |
Why?
|
| Fibroblasts | 1 | 2024 | 359 | 0.760 |
Why?
|
| Exosomes | 1 | 2022 | 56 | 0.750 |
Why?
|
| RNA, Messenger | 4 | 2022 | 1139 | 0.720 |
Why?
|
| Cell Line, Tumor | 7 | 2025 | 1436 | 0.680 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 634 | 0.620 |
Why?
|
| MicroRNAs | 1 | 2022 | 388 | 0.600 |
Why?
|
| Signal Transduction | 2 | 2024 | 1714 | 0.560 |
Why?
|
| Furans | 2 | 2017 | 30 | 0.550 |
Why?
|
| Naphthols | 1 | 2016 | 10 | 0.530 |
Why?
|
| Mice | 7 | 2025 | 5958 | 0.460 |
Why?
|
| Cell Proliferation | 4 | 2024 | 1029 | 0.450 |
Why?
|
| Mice, Nude | 4 | 2024 | 235 | 0.420 |
Why?
|
| Animals | 11 | 2025 | 13507 | 0.380 |
Why?
|
| HCT116 Cells | 3 | 2022 | 31 | 0.370 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2021 | 40 | 0.340 |
Why?
|
| Amides | 1 | 2025 | 37 | 0.240 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 404 | 0.240 |
Why?
|
| RNA-Binding Proteins | 2 | 2022 | 134 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2020 | 222 | 0.230 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 213 | 0.230 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2024 | 3 | 0.230 |
Why?
|
| beta Catenin | 1 | 2025 | 103 | 0.230 |
Why?
|
| Lysosomes | 1 | 2024 | 78 | 0.220 |
Why?
|
| Humans | 12 | 2025 | 52593 | 0.220 |
Why?
|
| Pyrimidines | 1 | 2025 | 200 | 0.220 |
Why?
|
| Colon | 1 | 2024 | 105 | 0.210 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 255 | 0.190 |
Why?
|
| Pyrvinium Compounds | 1 | 2021 | 1 | 0.190 |
Why?
|
| Anthelmintics | 1 | 2021 | 12 | 0.180 |
Why?
|
| Cytokines | 1 | 2024 | 626 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 1900 | 0.170 |
Why?
|
| Metabolomics | 1 | 2021 | 151 | 0.170 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 121 | 0.160 |
Why?
|
| Lung | 1 | 2022 | 501 | 0.150 |
Why?
|
| Cell Movement | 1 | 2020 | 276 | 0.150 |
Why?
|
| Phenanthrenes | 1 | 2017 | 13 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 2019 | 192 | 0.140 |
Why?
|
| Cell Survival | 1 | 2019 | 602 | 0.140 |
Why?
|
| Pancreatitis | 1 | 2018 | 65 | 0.130 |
Why?
|
| HT29 Cells | 1 | 2016 | 14 | 0.130 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2016 | 22 | 0.130 |
Why?
|
| Cyclooxygenase 2 | 1 | 2016 | 50 | 0.130 |
Why?
|
| Transfection | 1 | 2016 | 369 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1221 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1205 | 0.090 |
Why?
|
| Female | 4 | 2025 | 28262 | 0.080 |
Why?
|
| Neoplasms | 1 | 2020 | 1308 | 0.080 |
Why?
|
| Cytoplasm | 2 | 2020 | 93 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 857 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 96 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 136 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 673 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 310 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 86 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 278 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 78 | 0.040 |
Why?
|
| RNA Interference | 1 | 2019 | 186 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 218 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2019 | 101 | 0.040 |
Why?
|
| Papilloma | 1 | 2018 | 10 | 0.040 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2017 | 1 | 0.040 |
Why?
|
| AU Rich Elements | 1 | 2017 | 2 | 0.040 |
Why?
|
| Quinones | 1 | 2017 | 9 | 0.040 |
Why?
|
| Pancreas | 1 | 2018 | 71 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 69 | 0.030 |
Why?
|
| Point Mutation | 1 | 2017 | 69 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 55 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2017 | 44 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 70 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 46 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2017 | 179 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2017 | 253 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 112 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 564 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 800 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 2118 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1006 | 0.030 |
Why?
|
| United States | 1 | 2021 | 5227 | 0.020 |
Why?
|
| Male | 2 | 2019 | 26863 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 13096 | 0.010 |
Why?
|